Cystic Fibrosis Biotech Nivalis Therapeutics Files for $60 Million IPO

Published: May 14, 2015

Nivalis Therapeutics Files Registration Statement For Initial Public Offering Of Common Stock

BOULDER, Colo., May 13, 2015 /PRNewswire/ -- Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company committed to the discovery, development and commercialization of product candidates for patients with cystic fibrosis, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering (IPO) of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. In connection with the proposed IPO, Nivalis has applied to list its common stock on the NASDAQ Stock Market under the symbol "NVLS".

Cowen and Company and Stifel are acting as joint lead book-running managers for the proposed offering. Baird and H.C. Wainwright & Co. are acting as co-managers for the proposed offering.

The offering is being made only by means of a prospectus. A copy of the preliminary prospectus related to the offering, when available, may be obtained by directing requests to: Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140; or Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Attention: Syndicate, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Nivalis Therapeutics, Inc.

Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of product candidates for patients with cystic fibrosis. Cystic fibrosis is a life-shortening, genetic disease caused by mutations in the gene that encodes the cystic fibrosis transmembrane conductance regulator, or CFTR, a chloride channel that regulates the movement of salt and water into and out of cells.  The Nivalis lead product candidate, N91115, is a small molecule that addresses a defect in CFTR resulting from mutations in the CFTR gene.  Nivalis Therapeutics is dedicated to making a difference in the lives of patients with cystic fibrosis and their families.

Investor Relations Contact:
John Graziano
1-646-378-2942
jgraziano@troutgroup.com

Media Contact:
Lindsay Rocco
1-862-596-1304
lrocco@elixirhealthpr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nivalis-therapeutics-files-registration-statement-for-initial-public-offering-of-common-stock-300083057.html

SOURCE Nivalis Therapeutics, Inc.

Help employers find you! Check out all the jobs and post your resume.

Back to news